[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Lin CY, Yang SW, Lai CH: Primary malignant melanoma of the nasal cavity. Chang Gung Med J; 2003 Nov;26(11):857-62
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant melanoma is a highly lethal melanocytic neoplasm, usually affecting the skin.
  • The prognosis is generally poor, with a mean survival time of 3.5 years.
  • The usual treatment of choice is radical excision.
  • Radiotherapy and chemotherapy appear to have little effect.
  • Then, 6 courses of chemotherapy were further administered.
  • Unfortunately, regional cervical nodal involvement and pancreatic head metastases occurred 1.5 years after the diagnosis.
  • We have chosen to discuss this aggressive condition because of its rarity and also to emphasize the importance of its early detection through vigilant attention to nonspecific nasal symptoms.
  • [MeSH-major] Melanoma / pathology. Nasal Cavity. Nose Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14765758.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


2. Kim TM, Park YH, Lee SY, Kim JH, Kim DW, Im SA, Kim TY, Kim CW, Heo DS, Bang YJ, Chang KH, Kim NK: Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood; 2005 Dec 1;106(12):3785-90
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type.
  • This study was launched to determine the prognostic significance of local tumor invasiveness (LTI) in 114 patients diagnosed with stage I(E)/II(E) extranodal natural killer (NK)/T-cell lymphoma, nasal type (NTCL).
  • LTI was defined as bony invasion or destruction or tumor invasion of the skin.
  • Using multivariate analysis, factors associated with low probability of CR were the presence of LTI (P < .001), the presence of B symptoms (P = .003), and single-modality chemotherapy (P = .045).
  • [MeSH-major] Lymphoma, T-Cell / mortality. Neoplasm Invasiveness. Neoplasm Staging. Nose Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Humans. Killer Cells, Natural / pathology. Male. Middle Aged. Prognosis. Radiotherapy. Remission Induction. Survival Analysis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109779.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Kim TM, Heo DS: Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci; 2009 Dec;100(12):2242-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies.
  • Due to the clinical heterogeneity of NTCL, optimal treatment modalities and prognostic factors have been difficult to determine.
  • Ann Arbor staging for lymphomas and the International Prognostic Index (IPI) have been used to predict prognosis for UAT-NTCL; however, local tumor invasiveness (bony invasion or perforation or invasion of the overlying skin) is the most significant factor for poor outcomes in localized UAT-NTCL.
  • Thus, a new staging system is proposed: limited disease (stage I/II UAT-NTCL without local tumor invasiveness) and extensive disease (stage I/II with local invasiveness or stage III/IV disease of UAT NTCL, and non-UAT NTCL) based on treatment outcomes.
  • NTCL is resistant to anthracycline-based chemotherapy, whereas non-anthracycline combination chemotherapy (such as ifosfamide, methotrexate, etoposide, and prednisolone) has an activity against NTCL as either a front-line or as a second-line treatment.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758393.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


Advertisement
4. Stanway A, Rademaker M, Kennedy I, Newman P: Cutaneous B-cell lymphoma of nails, pinna and nose treated with chlorambucil. Australas J Dermatol; 2004 May;45(2):110-3
Hazardous Substances Data Bank. CHLORAMBUCIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous B-cell lymphoma of nails, pinna and nose treated with chlorambucil.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chlorambucil / therapeutic use. Ear Neoplasms / drug therapy. Ear, External / pathology. Lymphoma, B-Cell / drug therapy. Nail Diseases / drug therapy. Nose Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Neoplasm Recurrence, Local / drug therapy. Remission Induction

  • MedlinePlus Health Information. consumer health - Nail Diseases.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15068458.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 18D0SL7309 / Chlorambucil
  •  go-up   go-down


5. Bauman JE, Eaton KD, Martins RG: Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol; 2007 Jul;143(7):889-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
  • BACKGROUND: Squamous cell carcinoma of the skin (SCCS) is rarely encountered by medical oncologists owing to success of local therapies.
  • When advanced SCCS requires systemic palliation, treatment with conventional chemotherapy, such as cisplatin, is often precluded by a patient's age or medical comorbidities.
  • This drug, approved for treatment of squamous cell carcinoma of the upper aerodigestive tract as well as colorectal cancer, is well tolerated.
  • The drug was well tolerated, with the exception of acneiform rash requiring dose reduction in 1 patient.
  • Both patients had excellent responses to cetuximab: the first patient had complete response by week 16 of treatment and the second a near-complete response by week 12.
  • In both cases, initial response to cetuximab was evident by week 4 of therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Epidermal Growth Factor. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Combined Modality Therapy. Face / pathology. Female. Humans. Male. Nose / pathology. Scalp / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638733.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 62229-50-9 / Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


6. Nowak K, Stepniewski J, Milecki P, Szyfter W: [Merkel cell carcinoma of the nose]. Otolaryngol Pol; 2003;57(3):435-40
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Merkel cell carcinoma of the nose].
  • Despite an increasing number of reports Merkel cell carcinoma still is a rare neoplasm.
  • Surgery and adjuvant radiotherapy, chemotherapy appeared to provide optimal local control.
  • [MeSH-major] Carcinoma, Merkel Cell. Nose Neoplasms. Skin Neoplasms
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis / pathology. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14524191.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


7. Yu KN, Minai-Tehrani A, Chang SH, Hwang SK, Hong SH, Kim JE, Shin JY, Park SJ, Kim JH, Kwon JT, Jiang HL, Kang B, Kim D, Chae CH, Lee KH, Yoon TJ, Beck GR, Cho MH: Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice. PLoS One; 2010 Dec 22;5(12):e15623
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conventional therapies such as chemotherapy and surgery are somewhat successful, however, metastasis-related breast cancer morbidity remains high.
  • METHODOLOGY/PRINCIPAL FINDING: Aerosol of lentivirus-based small hairpin osteopontin was delivered into mice with breast cancer twice a week for 1 or 2 months using a nose-only inhalation system.
  • Our results showed that noninvasive targeting of pulmonary osteopontin or other specific genes responsible for cancer metastasis could be used as an effective therapeutic regimen for the treatment of metastatic epithelial tumors.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:14 [12605717.001]
  • [Cites] Anticancer Res. 1989 Sep-Oct;9(5):1291-9 [2686530.001]
  • [Cites] FASEB J. 1993 Dec;7(15):1475-82 [8262332.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):832-7 [8306346.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Ann N Y Acad Sci. 1995 Apr 21;760:299-301 [7785904.001]
  • [Cites] Crit Rev Oncog. 1996;7(3-4):261-91 [9258606.001]
  • [Cites] Invasion Metastasis. 1997;17(1):1-15 [9425320.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):998-1002 [9528847.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Oral Oncol. 1998 Nov;34(6):543-8 [9930369.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):368-73 [10050871.001]
  • [Cites] J Clin Pathol. 1998 Nov;51(11):798-802 [10193318.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7971-6 [15520204.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R680-8 [15535850.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2005 Mar;13(3):227-8 [15760565.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):608-22 [16442099.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):846-55 [16788158.001]
  • [Cites] J Cell Biochem. 2006 Sep 1;99(1):1-22 [16767697.001]
  • [Cites] Gene Ther. 2007 Dec;14(24):1721-30 [17960162.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5226-35 [18593923.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6A):2305-18 [18266970.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Jun 15;179(12):1131-40 [19286625.001]
  • [Cites] BMC Gastroenterol. 2009;9:73 [19804649.001]
  • [Cites] Cancer Gene Ther. 2009 Dec;16(12):892-9 [19461674.001]
  • [Cites] Cancer Immunol Immunother. 2010 Mar;59(3):355-66 [19690854.001]
  • [Cites] Curr Mol Med. 2010 Feb;10(1):71-81 [20205680.001]
  • [Cites] Surg Today. 2010 Apr;40(4):347-56 [20339989.001]
  • [Cites] Mol Cancer Ther. 2010 May;9(5):1180-7 [20423989.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Aug;136(8):1283-92 [20157733.001]
  • [Cites] Br J Cancer. 2010 Sep 7;103(6):861-9 [20823889.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2334-40 [10561295.001]
  • [Cites] Gene Ther. 2000 Jan;7(1):20-3 [10680011.001]
  • [Cites] Gene Ther. 2000 Mar;7(6):499-504 [10757023.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):271-8 [10832597.001]
  • [Cites] Mol Med. 2000 Mar;6(3):165-78 [10965493.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):135-46 [11005509.001]
  • [Cites] Nat Med. 2001 Jan;7(1):33-40 [11135613.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):188-200 [11157775.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):484-9 [11313979.001]
  • [Cites] Mol Ther. 2001 Apr;3(4):551-6 [11319917.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1055-61 [11342566.001]
  • [Cites] Cancer Gene Ther. 2002 Aug;9(8):692-9 [12136431.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):137-41 [12399124.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1235-44 [15067347.001]
  • [Cites] Cell Tissue Res. 1989 Apr;256(1):167-73 [2565770.001]
  • (PMID = 21203518.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR056090; United States / NCI NIH HHS / CA / R03 CA136059; United States / NIAMS NIH HHS / AR / AR056090; United States / NCI NIH HHS / CA / CA136059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC3008732
  •  go-up   go-down


8. Gieger TL, Théon AP, Werner JA, McEntee MC, Rassnick KM, DeCock HE: Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001). J Vet Intern Med; 2003 Sep-Oct;17(5):687-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Information on signalment, tumor grade and stage, treatment methods, and pattern of and time to failure and death was obtained from the medical record.
  • Twenty-three dogs were treated with combinations of radiotherapy, surgery, and chemotherapy; 1 dog received no treatment.
  • Mean and median survival times of treated dogs were 36 and 30 months, respectively.
  • Prognostic factors affecting survival time included tumor grade and presence of metastasis at diagnosis.
  • Variables, including sex, age, gross versus microscopic disease, and treatment type were not found to affect survival.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14529136.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Yu JB, Zuo Z, Tang Y, Zhao S, Zhang YC, Bi CF, Wang WY, Zhang WY, Wang L, Liu WP: Extranodal nasal-type natural killer/T-cell lymphoma of the skin: a clinicopathologic study of 16 cases in China. Hum Pathol; 2009 Jun;40(6):807-16
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal nasal-type natural killer/T-cell lymphoma of the skin: a clinicopathologic study of 16 cases in China.
  • Extranodal nasal-type natural killer/T-cell lymphoma presenting in skin, either primary or secondary, is relatively rare in China, accounting for about 4.1% of tumors.
  • The clinicopathologic features of the neoplasm are still poorly understood.
  • Thirteen of 15 patients received chemotherapy; a partial response was achieved in 10 patients; 10 (66.7%) of 15 patients died of the disease, and the average survival time was 6.6 months.
  • In patients with generalized skin lesions and extracutaneous involvement, the prognosis usually is poor.
  • [MeSH-major] Lymphoma, T-Cell / pathology. Nose / pathology. Nose Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200574.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Selim A, Khachemoune A, Lockshin NA: Angiosarcoma: a case report and review of the literature. Cutis; 2005 Nov;76(5):313-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiosarcoma is an aggressive neoplasm that predominantly affects elderly patients.
  • Most cases appear on the scalp and face de novo; however, trauma, longstanding lymphedema, and irradiation are predisposing factors.
  • Management includes a multidisciplinary team and may involve a combination of surgery, radiation, and chemotherapy tailored to the patient's age and associated comorbidities.
  • [MeSH-major] Hemangiosarcoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Male. Nose / pathology. Nose / surgery. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422466.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


11. Liang R: Diagnosis and management of primary nasal lymphoma of T-cell or NK-cell origin. Clin Lymphoma; 2000 Jun;1(1):33-7; discussion 38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of primary nasal lymphoma of T-cell or NK-cell origin.
  • The primary nasal natural killer cell (NK/T cell) lymphoma is histologically characterized by angiocentricity with invasion of blood vessels and blockage of blood vessels by lymphoma cells, resulting in marked ischemic necrosis of the normal and neoplastic tissues.
  • The tumor is locally invasive and may infiltrate surrounding tissues and organs, such as the orbits, nasopharynx, oropharynx, and palate.
  • The tumor may also disseminate to skin, gastrointestinal tract, and the testis at the time of progression.
  • Occasionally, other organ sites such as the skin are involved, sparing the nose, and it is then called the non-nasal type.
  • A high index of suspicion is required for the diagnosis of this disease.
  • Because of the small size of the specimen and the necrotic nature of the tumor, biopsy of the nasal tissue may not be easy to interpret.
  • The special stain for EBV in the tumor cells may also be helpful in making the correct diagnosis.
  • Response of primary nasal T-/NK-cell lymphoma to local treatment such as radiotherapy is often not satisfactory.
  • Combined chemotherapy and radiotherapy has been used and appears to be more effective.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / diagnosis. Nose Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / analysis. Diagnosis, Differential. Herpesvirus 4, Human / genetics. Humans. Immunophenotyping. Prognosis

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707809.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Number-of-references] 42
  •  go-up   go-down


12. Nishiura Y, Sakamoto K, Mihoki T, Takane Y, Maeda A, Miyajima Y, Nakashima T: [Autologous tumor-specific immunotherapy for recurrent malignant melanoma of the nasal cavity]. Nihon Jibiinkoka Gakkai Kaiho; 2006 Nov;109(11):781-4
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant melanoma usually occurs in tissues containing large numbers of melanocytes, such as the skin, mucosa and eye, and is one of the most highly malignant tumors known.
  • No satisfactory treatment results have ever been reported.
  • She had been diagnosed as having malignant melanoma in 1996 and under went radio-chemotherapy at our hospital.
  • Following systematic chemotherapy, 23 local injections of cytotoxic T lymphocytes were performed.
  • [MeSH-major] Immunotherapy / methods. Melanoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. T-Lymphocytes, Cytotoxic / transplantation
  • [MeSH-minor] Female. Humans. Interleukins / therapeutic use. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / therapy. Middle Aged. Neoplasm Recurrence, Local. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17165592.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Interleukins
  •  go-up   go-down


13. Leonard AL, Hanke CW: Treatment of giant keratoacanthoma with intralesional 5-fluorouracil. J Drugs Dermatol; 2006 May;5(5):454-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of giant keratoacanthoma with intralesional 5-fluorouracil.
  • Giant keratoacanthomas measure greater than 2 cm and have a predilection for the nose and eyelids.
  • As a result, they often present a significant therapeutic challenge.
  • A 36-year old woman was referred for evaluation of a 4.0 x 4.0 cm giant keratoacanthoma on the nose.
  • [MeSH-major] Fluorouracil / administration & dosage. Keratoacanthoma / drug therapy. Nose Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy. Skin Transplantation
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Gestational Age. Humans. Injections, Intralesional. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Prognosis. Reconstructive Surgical Procedures / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703783.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Ferenczi K, Summers P, Aubert P, Cooper B, Meyerson H, Cooper KD, Honda K: A case of CD30+ nasal natural killer/T-cell lymphoma. Am J Dermatopathol; 2008 Dec;30(6):567-71
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A skin biopsy revealed an atypical angiocentric mononuclear cell infiltrate.
  • However, flow cytometry of the skin lesion indicated that the cells were CD2+, CD4-, CD8-, and lacked surface CD3 more typical of a neoplasm of natural killer cells.
  • Further studies revealed that the cells were CD56+, T-cell-restricted intracellular antigen-1+, and contained Epstein-Barr virus sequences consistent with a nasal-type NK/T-cell lymphoma.
  • High titers of Epstein-Barr virus in the blood, evidence of sinonasal disease, and absence of a T-cell receptor gene rearrangement were additional features consistent with the diagnosis.
  • The patient had a very aggressive clinical course and, despite combination chemotherapy, died 8 months after the onset of skin lesions.
  • This case represents an example of nasal-type NK/T-cell lymphoma with expression of CD30.
  • When presenting in the skin, the phenotypic and morphologic features of this lymphoma may lead to an erroneous diagnosis of a CD30+ large-T-cell lymphoma.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, T-Cell, Cutaneous / diagnosis. Natural Killer T-Cells / immunology. Natural Killer T-Cells / pathology. Nose Neoplasms / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Immunophenotyping. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphoma, Large-Cell, Anaplastic / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033930.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  •  go-up   go-down


15. Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Iannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G, Intergruppo Italiano Linfomi: NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey. Ann Oncol; 2006 May;17(5):794-800
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey.
  • OBJECTIVE: To evaluate the clinical characteristics and outcome of NK/T-cell lymphoma 'nasal type' developed in Italian patients.
  • PATIENTS: Between 1997 and 2004, 26 new cases of NK/T-cell lymphoma 'nasal type' were diagnosed in 10 Italian Hematology institutions.
  • In 23 cases presentation at the onset was in the nasal cavity or adjacent structures, in two cases the lymphoma onset with skin lesions was followed successively by rhynopharyngeal dissemination, while the remaining case had bone marrow and lymph node involvement followed by oro-pharyngeal involvement.
  • Diagnosis was based on the finding of a NK/T-cell phenotype at the histological and immunophenotypic examination of oropharyngeal or cutaneous lesions.
  • All patients but one were treated with chemotherapy, alone in nine cases or associated to radiotherapy in 14 cases; two patients had chemotherapy, radiotherapy and surgery, while one patient underwent only surgery.
  • Chemotherapy was anthracycline-based in 17 out of 25 cases.
  • In those patients in whom radiotherapy was performed, radiation dosages ranged between 36 Gy and 47.5 Gy, with a median dosage of 40 Gy.
  • Nine patients (34%) were responsive to the treatments: six patients obtained a complete remission and other three a partial remission.
  • The remaining 17 patients resulted refractory or presented a limited response to therapy.
  • The median disease-free survival was 14 months and the median overall survival time was 9 months.
  • CONCLUSION: The results of this retrospective survey confirmed that NK/T-cell lymphoma 'nasal type' is a very rare lymphoma in the Italian population, and it is characterized by a very bad prognosis.
  • Due to the rarity of this disease, a standardized therapeutic approach is lacking.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497823.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Stell AJ, Dobson JM, Langmack K: Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid. J Small Anim Pract; 2001 Apr;42(4):164-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid.
  • A study was undertaken to investigate the treatment of superficial squamous cell carcinoma of the nasal planum, pinna and eyelid in cats by photodynamic therapy, using topical 5-aminolaevulinic acid cream, with subsequent exposure to red light of wavelength 635 nm, supplied by a light-emitting diode source.
  • After a single treatment, complete responses were seen in nine out of 10 nasal planum lesions, one out of two pinnal lesions and the eyelid lesion.
  • The overall complete response rate for lesions managed with a single photodynamic therapy treatment was 85 per cent.
  • Seven of the 11 lesions (63.6 per cent) showing a complete response subsequently recurred; the time to recurrence ranged from 19 to 56 weeks (median 21 weeks, mean 26.7 weeks).
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Squamous Cell / veterinary. Cat Diseases / drug therapy. Neoplasm Recurrence, Local / veterinary. Photochemotherapy / veterinary. Photosensitizing Agents / therapeutic use. Skin Neoplasms / veterinary
  • [MeSH-minor] Administration, Topical. Animals. Cats. Ear, External. Eyelid Neoplasms / drug therapy. Eyelid Neoplasms / veterinary. Light. Nose. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11327662.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


17. Berk V, Yildiz R, Akdemir UO, Akyurek N, Karabacak NI, Coskun U, Benekli M: Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules: utility of 18F-FDG PET in staging. Clin Nucl Med; 2008 May;33(5):365-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules: utility of 18F-FDG PET in staging.
  • The patient achieved complete remission with salvage l-asparaginase therapy after failing first-line standard anthracycline-based chemotherapy.
  • There is limited literature data on the use of the PET scan in the diagnosis and staging of extranodal nasal NK/T-cell lymphomas.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Extranodal NK-T-Cell / radionuclide imaging. Nose Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Skin Neoplasms / radionuclide imaging
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Staging. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18431160.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Kung B, Aftab S, Wood M, Rosen D: Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. Ear Nose Throat J; 2009 Jan;88(1):E7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient had had no known primary skin melanoma.
  • Postoperatively, he declined to undergo radio- and chemotherapy.
  • He developed ventilator-dependent respiratory failure and required a subtotal thyroidectomy for the placement of a tracheostomy tube.
  • [MeSH-major] Melanoma / secondary. Neoplasm Invasiveness / pathology. Thyroid Neoplasms / secondary. Thyroid Nodule / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Neck Dissection. Neoplasm Staging. Risk Assessment. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19172560.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


19. Caversaccio M, Aebi S: Medical treatment of nasal squamous papilloma with imiquimod cream. J Laryngol Otol; 2003 Sep;117(9):720-2
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical treatment of nasal squamous papilloma with imiquimod cream.
  • Numerous medical or surgical treatment modalities have been reported in the literature with variable, sometimes unsatisfactory results.
  • It is used for warts and other skin tumours on different locations of the body.
  • [MeSH-major] Aminoquinolines / therapeutic use. Interferon Inducers / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Nose Neoplasms / drug therapy. Papilloma / drug therapy
  • [MeSH-minor] Humans. Immunity, Cellular / drug effects. Immunocompromised Host. Male. Middle Aged. Ointments. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14561362.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Interferon Inducers; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


20. Biel M: Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg Med; 2006 Jun;38(5):349-55
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in photodynamic therapy for the treatment of head and neck cancers.
  • Photodynamic therapy (PDT) is an FDA-approved minimally invasive medical treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents that are relatively selectively concentrated in abnormal or neoplastic cells resulting in cell death.
  • At the present time, PDT has been approved for clinical treatment in the United States, European Union, Canada, Russia, and Japan.
  • In the United States, US Food and Drug administration approval has been given for the use of PDT in the treatment of Barrett's esophagus, obstructing esophageal carcinoma and early and obstructing tracheobronchial carcinoma using the photosensitizer Photofrin; actinic keratosis using the photosensitizer Levulan (aminolevulinic acid); and macular degeneration using the photosensitizer BPD.
  • In the EU the above noted indications have also been approved in addition to the treatment of early head and neck cancers and palliative treatment of head and neck cancer using the photosensitizer Foscan; and treatment of basal and squamous cell skin cancers using the photosensitizer Metvix.
  • [MeSH-major] Dihematoporphyrin Ether / therapeutic use. Head and Neck Neoplasms / therapy. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ambulatory Care. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy. Female. Humans. Male. Melanoma / therapy. Middle Aged. Minnesota / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Papilloma / therapy. Retrospective Studies. Sarcoma, Kaposi / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788923.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


21. Zhang YJ, Hu WH, Liu H, Cheng EC, Ren ZM, Xia YF, Cui NJ: [Clinical features and prognosis of nasal type NK/T cell lymphoma]. Zhonghua Zhong Liu Za Zhi; 2006 Jan;28(1):50-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognosis of nasal type NK/T cell lymphoma].
  • OBJECTIVE: To investigate the clinical features, treatment modalities and the prognosis of nasal type NK/T cell lymphoma.
  • Eleven patients by chemotherapy alone, 2 by radiotherapy alone and 2 aged patients by palliative chemotherapy or radiotherapy.
  • Radiotherapy was given by high energy photon ray combined with electron beam with a median curative dose of 56 Gy in conventional fractionation.
  • RESULTS: Median follow-up time for the 21 patients who were still alive was 22.5 months.
  • The overall remission rate (RR) after initial treatment was 66.7% (21 CR, 3 PR).
  • Chemotherapy alone got a CR rate of only 37.5%.
  • Radiotherapy was positively correlated with local control (P = 0.000) and time to disease progression (TTP, P = 0.002).
  • Skin and intestine were among the extranodal relapse sites.
  • Fifteen patients had highly aggressive tumors with a median survival time of only 5 months.
  • Univariate analysis showed that significant favorable survival prognostic factors were: radiotherapy (P = 0.001); lower risk International Prognostic Index (IPI, P = 0.001); complete remission after primary treatment (P = 0.000); pre-diagnostic history > 2 months (P = 0.024); and free of skin involvement (P = 0.034).
  • CONCLUSION: Most of nasal type NK/T cell lymphoma are in early stage when diagnosed.
  • Radiotherapy remains to be the mainstay of treatment.
  • Combined chemoradiotherapy needs further improvement for the progressive disease type.
  • Optimal prognostic factors and individualized treatment regimens need to be investigated.
  • [MeSH-major] Killer Cells, Natural. Lymphoma, T-Cell / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737622.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Omoti CE, Omoti AE: Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol; 2008 Sep;142(5):709-16
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The large cell lymphoma clone occurs by transformation of the original CLL clone in the majority of patients, and as a separate and independent neoplasm in fewer cases.
  • Extranodal Richter syndrome has also been reported to occur in the central nervous system, eye, gastrointestinal system, nose, skin, face, bone and bronchus.
  • The therapeutic options include cytoreductive therapy consisting of chemotherapy and immunotherapy, followed by allogeneic stem cell transplantation as postremission therapy.

  • Genetic Alliance. consumer health - Richter syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Feb;144(4):613; author reply 614-5 [19016718.001]
  • (PMID = 18492119.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 62
  •  go-up   go-down


23. Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, Manske U, Scholz A, Fierlbeck G, Mohr P, Ochsendorf F, Wagner G, Gaus W, Brzoska J, Jablonska S: Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur J Dermatol; 2002 Nov-Dec;12(6):558-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.
  • Although effective conventional therapies are available to treat basal cell carcinoma (BCC), undesirable side effects, including scarring, and in some cases permanent damage, often occur in problematic areas of the body, especially around the eyes, mouth, and cartilage of the nose and ears.
  • Secondary objectives included evaluating the effect of tumour type/size on response as well as residues, cosmetic results, and relapse rate after CR.
  • Intratumoural injections of rIFN-beta-1a (1.0 x 106 IU) were administered three times a week for 3 weeks.
  • The response was determined 16 weeks after start of treatment and the status of patients was followed for up to 5 years.
  • There was no significant difference between the response rates for patients with solid or other BETACC tumour types.
  • The cosmetic result of treatment was rated as good or very good in 83% of responders.
  • All patients showed local inflammatory reactions, which were generally considered to be the adverse drug reactions (ADRs).
  • These results show that intratumoural injections of rIFN-beta-1a are effective in the treatment of BETACC in the majority of patients.
  • In addition, rIFN-beta-1a is safe and generally well tolerated. rIFN-beta-1a represents an effective alternative treatment for BETACC.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / drug therapy. Interferon Type I / administration & dosage. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Injections, Intralesional. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Statistics, Nonparametric. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12459527.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Interferon Type I; 0 / Recombinant Proteins
  •  go-up   go-down


24. Ferreira I, Rahal SC, Rocha NS, Gouveia AH, Corrêa TP, Carvalho YK, Bagnato VS: Hematoporphyrin-based photodynamic therapy for cutaneous squamous cell carcinoma in cats. Vet Dermatol; 2009 Jun;20(3):174-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematoporphyrin-based photodynamic therapy for cutaneous squamous cell carcinoma in cats.
  • Photodynamic therapy (PDT) using a haematoporphyrin derivative (Photogem, General Physics Institute and clustes Ltda) as photosensitizer and light emitting diodes (LEDs) as the light source was evaluated in 12 cats with cutaneous squamous cell carcinoma.
  • Highly invasive tumours of the nose and nasal planum also showed no response, after two treatments (n = 2).
  • Two cats showed partial response and one complete response with one application of therapy 30 days after nasal surgery.
  • [MeSH-major] Carcinoma, Squamous Cell / veterinary. Cat Diseases / drug therapy. Hematoporphyrin Photoradiation / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Combined Modality Therapy / veterinary. Female. Male. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / veterinary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374724.001).
  • [ISSN] 1365-3164
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


25. Caron J, Dereure O, Kerob D, Lebbe C, Guillot B: Metastatic basal cell carcinoma: report of two cases treated with cetuximab. Br J Dermatol; 2009 Sep;161(3):702-3
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Nose Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Axilla. Cetuximab. Fatal Outcome. HIV Seropositivity / complications. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575727.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; PQX0D8J21J / Cetuximab
  •  go-up   go-down


26. Martires KJ, Capaldi L, Pattee SF, Maloney ME, Bordeaux JS: Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production. Arch Dermatol; 2010 Sep;146(9):1047-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production.
  • [MeSH-major] Aminoquinolines / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Melanoma, Amelanotic / drug therapy. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Nose. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855714.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down






Advertisement